| Assessment Status |
NCPE assessment ongoing |
| HTA ID |
24020 |
| Drug |
Sparsentan |
| Brand |
Filspari® |
| Indication |
For the treatment of adults with primary immunoglobulin A (IgA) nephropathy with a urine protein excretion >1.0 g/day (or urine protein-to-creatine ratio ≥0.75 g/g). |
| Rapid review commissioned |
30/05/2024 |
| Rapid review completed |
26/06/2024 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of sparsentan compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
31/07/2024 |
| Pre-submission consultation with Applicant |
01/10/2024 |
| Full submission received from Applicant |
12/12/2024 |
| Preliminary review sent to Applicant |
18/09/2025 |
| NCPE assessment re-commenced |
17/10/2025 |
| Follow-up to preliminary review sent to Applicant |
23/10/2025 |
| NCPE assessment re-commenced |
03/11/2025 |
